DNA Q4 2021 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$148M+363.2% YoY

Gross Profit

$82M55.2% margin

Operating Income

-$1.7B-1134.5% margin

Net Income

-$1.6B-1077.9% margin

EPS (Diluted)

$-43.34

QoQ Revenue Growth

+91.3%

Cash Flow

Operating Cash Flow

-$166M

Free Cash Flow

-$171M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$504M

Stockholders' Equity

$1.5B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$148M	$32M	+363.2%
Gross Profit	$82M	$18M	+349.7%
Operating Income	-$1.7B	-$56M	-2914.5%
Net Income	-$1.6B	-$47M	-3311.2%

Revenue Segments

Service

$106M93%

Product

$8M7%